AbbVie Inc. (ABBV)

AbbVie Inc. (ABBV)

Postby winston » Wed Sep 23, 2015 7:33 pm

not vested

Tech Bargain No. 4: AbbVie Inc. (NYSE: ABBV)

Investors have worried lately that AbbVie Inc. (NYSE: ABBV) is too dependent on Humira (adalimubab), the best-selling drug in the world with sales last year of more than $12.5 billion.

Patents on the anti-inflammatory begin to expire late next year.

However, AbbVie just made a $21 billion acquisition of Pharmcyclics Inc. The buyout added Imbruvica (ibrutinib), a promising leukemia drug, to its portfolio.

And in just the past two weeks, AbbVie announced that it is seeking to expand Imbruvica in the United States to include front-line treatment of chronic lymphocytic leukemia – the most common form of the disease.

The company is making some shrewd strategic partnerships right now, too…

It has partnered with Google Inc.'s (Nasdaq: GOOG, GOOGL) secretive California Life Company, better known as Calico. The two companies have agreed to invest $1.5 billion in drug research and will focus on genetic data to treat age-related diseases.

With a $98 billion market cap, the STOCK TRADES at $59.50. It has a 39% return on equity and recently increased its quarterly earnings by 24%. On a forward earnings basis, it TRADES at a nearly 30% discount to the S&P 500.

Source: Money Morning
It's all about "how much you made when you were right" & "how little you lost when you were wrong"
User avatar
winston
Billionaire Boss
 
Posts: 118528
Joined: Wed May 07, 2008 9:28 am

Re: AbbVie Inc. (ABBV)

Postby winston » Thu Dec 10, 2020 8:43 pm

not vested

THE TAILWIND IN HEALTH CARE IS STILL GOING STRONG

Today, we're looking at a company that thrives as the population ages...

As Boomers get older, they'll need to spend more on medical care, such as prescriptions and doctors' visits. This trend is still in place – and today's company is set to benefit...

AbbVie (ABBV) is a $190 billion pharmaceutical giant. Its drugs treat diseases common among the elderly such as rheumatoid arthritis and prostate cancer.

In fact, its second-most lucrative drug this quarter, Imbruvica, treats chronic lymphocytic leukemia, which mainly affects older adults.

These medications help people live longer and improve their quality of life... And they bring in revenue as well. AbbVie reported total sales of $12.9 billion in the third quarter, a 52% increase year over year (partly boosted by a recent acquisition).

As you can see in today's chart, shares of ABBV are soaring. The stock is up nearly 70% from its mid-March lows, recently hitting new highs. As Baby Boomers continue to pay more for medical expenses, ABBV should perform well...

Source: Daily Wealth
It's all about "how much you made when you were right" & "how little you lost when you were wrong"
User avatar
winston
Billionaire Boss
 
Posts: 118528
Joined: Wed May 07, 2008 9:28 am


Return to A to D

Who is online

Users browsing this forum: No registered users and 10 guests

cron